Navigation Links
Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results
Date:8/4/2011

SAN DIEGO, Aug. 4, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced its financial results for the quarter ended June 30, 2011.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Optimer reported net loss for the second quarter of 2011 of $24.2 million, or ($0.52) per share on both a basic and diluted basis, as compared to a net loss for the second quarter of 2010 of $10.1 million, or ($0.26) per share on both a basic and diluted basis.  The increase in net loss was primarily due to increases in marketing, research and development, and general and administrative expenses related to the U.S. approval and third quarter launch of DIFICID™.

Marketing expenses for the second quarter of 2011 increased $6.3 million compared to the second quarter of 2010 due to Optimer's efforts to establish a commercial infrastructure and prepare for the launch of DIFICID, including the hiring of approximately 100 marketing and sales staff.  General and administrative expenses increased $3.8 million compared to the second quarter of 2010, primarily because of higher compensation expense due to additional headcount as well as higher recruitment, consulting, facilities and legal expenses.  Research and development expenses increased $4.2 million compared to the second quarter of 2010 due to higher health economics research, pharmacovigilance, medical affairs  and publication expenses, as well as higher research and development expenses by OBI associated with the OPT-822 Phase 2/3 trial in breast cancer.

As of June 30, 2011, Optimer held cash, cash equivalents and short-term investments of $157.8 million and had 46,602,501 shares outstanding.

"The second quarter culminated with the FDA approval of DIFICID for the treatment of C. difficile-associated diarrhea, or CDAD, in patients over the age of 18, which includes clear differentiation and superiority over oral vancomycin in sustained clinical response 25 days after the end of therapy," said Pedro Lichtinger, President and CEO of Optimer.  "Our success with the FDA approval and the recent launch of DIFICID can be attributed to thorough preparation and execution by our team. We remain highly focused on the successful introduction of DIFICID to physicians and patients, and on establishing DIFICID, based on the clinical experience to date, as the preferred treatment for CDAD patients."

Second Quarter and Recent Highlights

  • On May 27, the U.S. Food and Drug Administration approved Optimer's antibacterial drug DIFICID™ (fidaxomicin) Tablets for the treatment of CDAD in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease.
  • On July 18, Optimer announced the commercial launch of DIFICID™ Tablets for the treatment of CDAD in patients 18 years of age and older.
  • Optimer entered into a co-promotion agreement with Cubist Pharmaceuticals to market DIFICID for the treatment of CDAD in the U.S. to help maximize the impact of, and de-risk, the commercial launch of DIFICID.
  • Optimer also presented additional data analysis from the DIFICID Phase 3 clinical trials highlighting risk factors associated with negative outcomes in patients with CDAD such as advanced age and immunosuppression. Data were presented at key scientific conferences including the European Congress of Clinical Microbiology and Infectious Diseases, Digestive Disease Week and the Annual Meeting of the American Geriatric Society.

  • About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and is commercializing DIFICID™ (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has filed a marketing authorization application with the European Medicines Agency for fidaxomicin. Optimer's clinical pipeline includes Pruvel™, a product in the fluoroquinolone class of antibiotics that has completed Phase 3 trials as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

    Forward Looking StatementsStatements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation statements related to Optimer's plans to commercialize DIFICID, including with its co-promotion partner, the incidence of CDAD, and Optimer's expectations regarding the impact of the commercial launch of DIFICID. Words such as "believes", "would", "anticipates", "plans", "expects", "may", "intend", "will", and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. These forward-looking statements are based on management's expectations on the date of this release.  Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: the implementation and continuation of Optimer's co-promotion agreement with Cubist, Optimer's and Cubist's ability to commercialize DIFICID according to Optimer's expected scope and timelines, the ability of Optimer and its third party contractors to manufacture and supply sufficient quantities of DIFICID in accordance with Good Manufacturing Practices to meet demand, whether healthcare professionals will prescribe DIFICID, whether DIFICID will receive reimbursement coverage from healthcare payors and government agencies, the extent to which DIFICID will be accepted on hospital formularies, Optimer's ability to successfully manage a sales and marketing organization and other risks detailed in Optimer's filings with the Securities and Exchange Commission.

    Contacts:
    Optimer Pharmaceuticals, Inc.
    David Walsey, Vice President, Investor Relations and Corporate Communications
    858-909-0736

    Canale Communications, Inc.
    Jason I. Spark, Senior Vice President
    619-849-6005Optimer Pharmaceuticals, Inc.Consolidated Statements of Operations(unaudited) Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, 2011201020112010Revenues:Licensing

    $
    - $
    - $69,165,000 $
    - Research grants

    33,294357,436144,933654,873   Total revenues

    33,294357,43669,309,933654,873Cost and expenses:   Cost of licensing

    --4,273,532-Research and development

    10,570,6366,419,25119,041,14517,780,830Marketing

    6,974,322656,46410,407,915925,058General and administrative

    7,506,5253,686,44215,786,7076,075,154Total operating expenses

    25,051,48310,762,15749,509,29924,781,042Income (loss) from operations

    (25,018,189)(10,404,721)19,800,634(24,126,169)Interest income and other, net

    95,86053,719119,10278,497Consolidated net income (loss)

    $ (24,922,329)$  (10,351,002)$19,919,736$(24,047,672)Net loss attributable to noncontrolling interest

    683,483290,105974,288491,020Net income (loss) attributable to Optimer Pharmaceuticals, Inc.

    $ (24,238,846)$  (10,060,897)$20,894,024$(23,556,652)Net income (loss) per share - basic

    $
    (0.52)$
    (0.26)$
    .47$
    (0.64)Net income (loss) per share - diluted

    $
    (0.52)$
    (0.26)$
    .46$
    (0.64)Weighted average number of shares used to compute net  income (loss) per share - basic

    46,479,39538,306,91044,581,01036,663,380Weighted average number of shares used to compute net  income (loss) per share - diluted

    46,479,39538,306,91045,447,26136,663,380Optimer Pharmaceuticals, Inc.Condensed Consolidated Balance SheetsJune 30December 31,20112010(unaudited)ASSETSCurrent assets:Cash and cash equivalents

    $   61,402,529$   19,861,924Short-term investments

    96,391,74229,553,506Research grant and other  receivables

    78,95753,552Inventory

    1,369,482-Prepaid expenses and other current assets

    5,843,511463,307Total current assets

    165,086,22149,932,289Property and equipment, net

    2,172,443697,683Long-term investments

    882,000882,000Other assets

    1,242,523508,190Total assets

    $ 169,383,187$   52,020,162LIABILITIES  AND STOCKHOLDERS' EQUITY Current liabilities:Accounts payable

    $
    ,738,492$
    2,307,820Accrued expenses

    5,080,6792,385,046Total current liabilities

    11,819,1714,692,866Deferred rent

    183,515141,138Stockholders’ equity

    157,380,50147,186,158Total liabilities and stockholders’ equity

    $ 169,383,187$   52,020,162
    '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
    2. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    3. Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
    4. Optimer Pharmaceuticals Reports First Quarter 2011 Financial Results
    5. Optimer Pharmaceuticals Expands Senior Management Team
    6. Optimer Pharmaceuticals to Present at May 2011 Investor Conferences
    7. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
    8. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
    9. Trading Halted Today in Optimer Pharmaceuticals Stock
    10. Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
    11. Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
    (Date:9/9/2017)... WASHINGTON , Sept. 8, 2017 ... Mobile MRI Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, ... to Washington, D.C. offering free MRI brain scans to the public.Where:  ... – will be parked at 501 K Street NW, Washington, D.C.What:BTF brings ...
    (Date:9/7/2017)... Texas , Sept. 7, 2017 ... science focused on fulfilling the promise of precision ... further validate the benefits of its molecular profiling ... study utilized comprehensive genomic profiling plus (CGP+) with ... individual patient,s tumor on a molecular level, leading ...
    Breaking Medicine Technology:
    (Date:9/20/2017)... ... 2017 , ... Recognising that in today’s busy world consumers ... positive results in just three weeks. Setting the groundwork for a healthier lifestyle, ... into hectic work and family schedules, participants can lose up to 15lbs during ...
    (Date:9/20/2017)... ... September 20, 2017 , ... Ron Norman, CEO ... marketers this week about the value of senior executives, pointed to a quote ... in business has brought us to the present and will lead us into ...
    (Date:9/20/2017)... ... ... “Monique”: is the story of Monique, whose mother’s deteriorating physical condition forces the ... has owned four beauty salons and written a book regarding the author’s success in ... , “The doctor’s office was only three blocks away, and she could walk it, ...
    (Date:9/19/2017)... ... September 19, 2017 , ... Trusted debt-reduction firm CreditAssociates, LLC has ... translating to in excess of $835 million in resolved debt for its clients. , ... are some of the categories of debt settled by the company. With more than ...
    (Date:9/19/2017)... ... September 19, 2017 , ... The ... Canyon Ranch to its recently formed Corporate Roundtable, a group of individuals ... and a sustainable world. , Canyon Ranch is a unique collection of lifestyle-based ...
    Breaking Medicine News(10 mins):